TCM Biotech International Corp. (TPEX:4169)
Taiwan
· Delayed Price · Currency is TWD 179.00
-2.00 (-1.10%)
At close: Dec 5, 2025
TCM Biotech International Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 682.4 | 666.53 | 969.62 | 802.42 | 702.05 | 737.08 | Upgrade
|
| Revenue Growth (YoY) | -8.63% | -31.26% | 20.84% | 14.30% | -4.75% | 29.62% | Upgrade
|
| Cost of Revenue | 361.66 | 339.22 | 489.45 | 353.93 | 343.33 | 368.15 | Upgrade
|
| Gross Profit | 320.74 | 327.31 | 480.17 | 448.49 | 358.72 | 368.92 | Upgrade
|
| Selling, General & Admin | 209.27 | 224.09 | 380.38 | 340.9 | 276.14 | 259.59 | Upgrade
|
| Research & Development | 90.79 | 93.22 | 77.46 | 81.8 | 80.45 | 71.53 | Upgrade
|
| Operating Expenses | 298.3 | 316.61 | 457.84 | 423.19 | 356.59 | 331.87 | Upgrade
|
| Operating Income | 22.44 | 10.7 | 22.33 | 25.3 | 2.13 | 37.05 | Upgrade
|
| Interest Expense | -0.9 | -1.61 | -2.77 | -2.39 | -1.97 | -1.95 | Upgrade
|
| Interest & Investment Income | 5.79 | 4.69 | 1.55 | 0.14 | 0.04 | 0.07 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | 0.01 | 0.44 | -0.55 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.47 | 11.24 | 0.93 | 0.07 | 0.71 | 0.16 | Upgrade
|
| EBT Excluding Unusual Items | 23.86 | 25.02 | 22.03 | 23.13 | 1.35 | 34.78 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.91 | 1.35 | Upgrade
|
| Pretax Income | 23.86 | 25.02 | 22.03 | 23.13 | 2.26 | 36.13 | Upgrade
|
| Income Tax Expense | 2.78 | 4.01 | 3.46 | 4.86 | 0.38 | 10.59 | Upgrade
|
| Net Income | 21.08 | 21.01 | 18.57 | 18.27 | 1.87 | 25.54 | Upgrade
|
| Net Income to Common | 21.08 | 21.01 | 18.57 | 18.27 | 1.87 | 25.54 | Upgrade
|
| Net Income Growth | -26.29% | 13.11% | 1.69% | 875.17% | -92.67% | 292.17% | Upgrade
|
| Shares Outstanding (Basic) | 59 | 59 | 53 | 49 | 49 | 48 | Upgrade
|
| Shares Outstanding (Diluted) | 59 | 59 | 53 | 49 | 49 | 48 | Upgrade
|
| Shares Change (YoY) | 0.87% | 11.37% | 8.03% | 0.89% | 0.42% | -0.03% | Upgrade
|
| EPS (Basic) | 0.36 | 0.36 | 0.35 | 0.37 | 0.04 | 0.53 | Upgrade
|
| EPS (Diluted) | 0.36 | 0.36 | 0.35 | 0.37 | 0.04 | 0.52 | Upgrade
|
| EPS Growth | -26.93% | 1.66% | -5.41% | 861.49% | -92.66% | 289.82% | Upgrade
|
| Free Cash Flow | 36.37 | 159.42 | -41.51 | 48.46 | 11.19 | 71.96 | Upgrade
|
| Free Cash Flow Per Share | 0.62 | 2.70 | -0.78 | 0.99 | 0.23 | 1.49 | Upgrade
|
| Dividend Per Share | 0.350 | 0.350 | 0.285 | 0.033 | - | 0.349 | Upgrade
|
| Dividend Growth | 22.81% | 22.81% | 763.64% | - | - | -10.00% | Upgrade
|
| Gross Margin | 47.00% | 49.11% | 49.52% | 55.89% | 51.10% | 50.05% | Upgrade
|
| Operating Margin | 3.29% | 1.60% | 2.30% | 3.15% | 0.30% | 5.03% | Upgrade
|
| Profit Margin | 3.09% | 3.15% | 1.92% | 2.28% | 0.27% | 3.46% | Upgrade
|
| Free Cash Flow Margin | 5.33% | 23.92% | -4.28% | 6.04% | 1.59% | 9.76% | Upgrade
|
| EBITDA | 40.6 | 28.61 | 39.52 | 40.86 | 16.42 | 50.35 | Upgrade
|
| EBITDA Margin | 5.95% | 4.29% | 4.08% | 5.09% | 2.34% | 6.83% | Upgrade
|
| D&A For EBITDA | 18.16 | 17.92 | 17.19 | 15.56 | 14.29 | 13.3 | Upgrade
|
| EBIT | 22.44 | 10.7 | 22.33 | 25.3 | 2.13 | 37.05 | Upgrade
|
| EBIT Margin | 3.29% | 1.60% | 2.30% | 3.15% | 0.30% | 5.03% | Upgrade
|
| Effective Tax Rate | 11.65% | 16.02% | 15.70% | 21.02% | 17.01% | 29.31% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.